DVA
HealthcareDaVita Inc. · Medical - Care Facilities · $13B
What is DaVita Inc.?
DaVita Inc. is a leading U.S. provider of kidney dialysis services, operating one of the largest networks of outpatient dialysis centers in the country and internationally.
DaVita generates revenue by operating outpatient dialysis centers, delivering home-based and hospital inpatient dialysis, and providing related laboratory and management services. The company also offers integrated kidney care programs and vascular access services, serving patients with chronic kidney failure across the United States and in select international markets.
Incorporated in 1994 and headquartered in Denver, Colorado, DaVita has grown into a major force in kidney care.
- Outpatient hemodialysis centers
- Home-based dialysis programs
- Acute inpatient dialysis in hospitals
- Integrated kidney care and disease management
Is DVA a Good Stock to Buy?
UQS Score rates DVA as Below Average overall.
Valuation stands out as the most favorable pillar, suggesting the stock may be priced attractively relative to its fundamentals. Quality and Moat both register as Neutral, reflecting a stable but undifferentiated competitive position in a regulated, essential-services market.
Growth and Risk are both rated Weak, pointing to limited expansion prospects and meaningful operational or financial vulnerabilities that investors should weigh carefully.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DVA pay dividends?
No — DaVita Inc. does not currently pay a dividend.
DaVita does not currently pay a dividend. The company's capital tends to be directed toward operating its large dialysis network, managing debt obligations, and funding share repurchases rather than distributing cash to shareholders.
When does DVA report earnings?
DaVita reports earnings on a quarterly cadence, consistent with standard practice for U.S.-listed equities.
Results have reflected the pressures of labor costs and reimbursement dynamics common across the dialysis industry. Revenue visibility is relatively stable given the chronic, recurring nature of kidney disease treatment.
For the most recent quarter's results, visit DaVita's investor relations page directly.
DVA Price History
+24.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in DaVita Inc.?
Based on DaVita Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does DaVita do?
DaVita operates outpatient kidney dialysis centers and provides related services including home dialysis, hospital inpatient dialysis, laboratory testing, and integrated kidney care programs. It serves patients with chronic kidney failure across the U.S. and in select international markets.
Does DVA pay dividends?
No, DaVita does not currently pay a dividend. The company prioritizes reinvestment in its dialysis network and uses available capital for debt management and share repurchases rather than direct income distributions to shareholders.
When does DVA report earnings?
DaVita follows a standard quarterly earnings schedule. For confirmed dates and the latest financial releases, check DaVita's official investor relations page, as our data source does not cover specific upcoming earnings dates.
Is DVA a good stock to buy?
DVA carries a Below Average UQS Score, driven by Weak Growth and Risk ratings. The Valuation pillar is Attractive, which may interest certain investors. The complete pillar breakdown is available to UQS Pro members.
Is DVA overvalued?
The UQS Valuation pillar for DVA is rated Attractive, suggesting the stock does not appear expensive relative to its fundamentals at current levels. Full valuation metrics are accessible through a UQS Pro account.
What is DVA's market cap bracket?
DaVita is classified as a mid-cap company, placing it between smaller regional healthcare operators and the largest hospital or managed-care conglomerates in the sector.
Is DVA a long-term quality investment?
From a long-term quality perspective, DVA's Neutral Quality and Moat ratings suggest a stable but not standout business. Weak Growth and Risk scores are meaningful considerations for investors with a multi-year horizon. Pro members can view the full analysis.
What sector does DVA belong to?
DaVita operates in the Healthcare sector, specifically within the kidney care and dialysis services segment — a niche driven by the chronic and recurring nature of end-stage renal disease treatment.
Unlock Full DVA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for DVA
- ✓Access detailed financial metrics across Quality, Growth, Moat, Risk, and Valuation
- ✓Compare DVA against peers in the Healthcare sector
- ✓Get the full analyst-style report available to Pro members
Pro Analysis
DVA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | 49.6 | 45.6 | 51.0 | 33.2 | 35.6 | 89.7 | +1.0 |
| May 10, 2026 | 48.6 | 44.2 | 51.0 | 33.2 | 35.6 | 85.1 | +3.3 |
| May 9, 2026 | 45.3 | 44.2 | 51.0 | 16.6 | 35.6 | 85.3 | -4.7 |
| May 1, 2026 | 50.0 | 45.4 | 51.0 | 32.8 | 34.4 | 94.6 | +0.2 |
| Apr 26, 2026 | 49.8 | 45.4 | 51.0 | 32.8 | 34.4 | 93.3 | -0.1 |
| Apr 24, 2026 | 49.9 | 45.4 | 51.0 | 32.8 | 34.4 | 94.0 | +0.1 |
| Apr 23, 2026 | 49.8 | 45.4 | 51.0 | 32.8 | 34.4 | 93.3 | -0.1 |
| Apr 18, 2026 | 49.9 | 45.4 | 51.0 | 32.8 | 34.4 | 93.8 | -0.9 |
| Apr 2, 2026 | 50.8 | 45.4 | 51.0 | 32.8 | 34.4 | 100.0 | — |
DVA — Pillar Breakdown
Quality
— 45.6/100 (25%)DaVita Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 33.6/100 (20%)DaVita Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 35.6/100 (15%)DaVita Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 90.1/100 (15%)DaVita Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 51/100 (25%)DaVita Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DVA.
Score Composition
Financial Data
More Stock Analysis
How is the DVA UQS Score Calculated?
The UQS (Unified Quality Score) for DaVita Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses DaVita Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether DaVita Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.